Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on developing novel cardiopulmonary therapies. Its pipeline includes TNX-101, TNX-102, and TNX-103 (levosimendan), which have completed Phase II clinical trials for treating patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension. Additionally, the company is developing TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Tenax Therapeutics is headquartered in Chapel Hill, North Carolina, and was originally founded in 1967. It was formerly known as Oxygen Biotherapeutics, Inc. before rebranding in September 2014.

Tenax Therapeutics, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol TENX. Its securities trade in United States Dollars (USD). The company is based in the United States, and its stock is accessible to investors through major US brokerage platforms.

Tenax Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research and development of pharmaceutical therapies, particularly for cardiopulmonary conditions and chronic myeloid leukemia. The company is in the development stage, meaning its products have not yet received regulatory approval for commercial sale.

Tenax Therapeutics is headquartered in Chapel Hill, North Carolina, United States. The company was founded in 1967 and has undergone a name change: it was formerly known as Oxygen Biotherapeutics, Inc. before rebranding to Tenax Therapeutics in September 2014. The company primarily serves the US market, focusing on developing therapies for unmet medical needs in cardiopulmonary diseases and oncology.

Tenax Therapeutics' main product candidates include TNX-101, TNX-102, and TNX-103, which are formulations of levosimendan. These have completed Phase II clinical trials for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension. Another candidate is TNX-201 (imatinib), a tyrosine kinase inhibitor intended for chronic myeloid leukemia. All candidates are in development, and the company has not yet commercialized any products.